ID | 58566 |
FullText URL | |
Author |
Iwamoto, Takayuki
Department of Breast and Endocrine Surgery, Okayama University Hospital
Kaken ID
researchmap
Fujisawa, Tomomi
Department of Breast Oncology, Gunma Prefectural Cancer Center
Araki, Kazuhiro
Department of Medical Oncology, Gunma Prefectural Cancer Center
Sakamaki, Kentaro
Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo
Sangai, Takafumi
Department of Breast and Thyroid Surgery, Chiba University Hospital
Kikawa, Yuichiro
Department of Breast Surgery, Kobe City Medical Center General Hospital
Takao, Shintaro
Department of Breast Surgery, Hyogo Cancer Center
Nishimura, Reiki
Department of Breast Oncology, Kumamoto Shinto General Hospital
Takahashi, Masato
Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center
Aihara, Tomohiko
Breast Center, Aihara Hospital
Mukai, Hirofumi
Division of Breast and Medical Oncology, National Cancer Center Hospital East
aira, Naruto
Department of Breast and Endocrine Surgery, Okayama University Hospital,
|
Abstract | Purpose
Second-line endocrine therapy (ET) for estrogen receptor (ER)-positive and human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) is offered based on the response to first-line ET. However, no clinical trials have evaluated the efficacy and safety of secondary ETs in patients with poor responses to initial ET. This study evaluated the efficacy of second-line ET in ER-positive and HER2-negative postmenopausal MBC patients with low or very low sensitivity to initial ET.
Methods
This multicenter prospective observational cohort study evaluated the response of 49 patients to second-line ETs in postmenopausal MBC patients with low or very low sensitivity to initial ET. The primary endpoint was the clinical benefit rate (CBR) for 24 weeks.
Results
Of the 49 patients assessed, 40 (82%) received fulvestrant in the second line, 5 (10%) received selective estrogen receptor modulators, 3 (6%) received aromatase inhibitors (AIs) alone, and 1 received everolimus with a steroidal AI. The overall CBR was 44.9% [90% confidence interval (CI): 34.6–57.6, p = 0.009]; CBR demonstrated similar significance across the progesterone receptor-positive (n = 39, 51.3%, 90% CI: 39.6–65.2, p = 0.002), very low sensitivity (n = 17, 58.8%, 90% CI: 42.0–78.8, p = 0.003), and non-visceral metastases (n = 25, 48.0%, 90% CI: 34.1–65.9, p = 0.018) groups. The median progression-free survival was 7.1 months (95% CI: 5.6–10.6).
Conclusion
Second-line ET might be a viable treatment option for postmenopausal patients with MBC with low and very low sensitivity to initial ET. Future studies based on larger and independent cohorts are needed to validate these findings.
|
Keywords | Metastatic breast cancer
Endocrine therapies
Estrogen receptor-positive
HER2-negative
Resistance
|
Published Date | 2020-05-11
|
Publication Title |
Breast Cancer
|
Volume | volume27
|
Issue | issue5
|
Publisher | Springer
|
Start Page | 973
|
End Page | 981
|
ISSN | 13406868
|
NCID | AA1103354X
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
File Version | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1007/s12282-020-01095-y
|